INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!
Incyte/ Novartis’ JAKAVI (ruxolitinib, JAK 1/2 inhibitor, Registered for MF; PhII in PV/ET; JAKAFI – approved in the US) has received a positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of disease-related splenomegaly or symptoms of primary myelofibrosis (MF), post- polycythemia vera MF or post-essential thrombocythemia MF. This event triggers $40m milestone payment from Novartis (Ex-US rights), and INCY will received a second payment of $60m upon an achievement of reimbursement and pricing policy in specific EU countries. In FY12 guidance, these milestones were not included which … For more details, please read our report released on April 20, 2012 on INCY, titled “Cheers for INCY - JAKAVI Receives CHMP Nod!”
COMPANIES MENTIONED
INCYTE, NOVARTIS
INCYTE, NOVARTIS
